Volociximab

Summary

Volociximab (CHEMBL2108061) is a phase-3 clinical-stage antibody targeting ITGA5; indicated across 7 conditions including melanoma and exocrine pancreatic carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Targets: 1 (ITGA5)
• Indications: 7 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108061
Name	Volociximab
Type	Antibody
Max phase	3

Also known as: M-200, M200, Volociximab, VOLOCIXIMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ITGA5	integrin, alpha 5 subunit (fibronectin receptor, alpha polypeptide)	Binding	9.49	2%	P08648
	integrin α5β1	Binding	9.49

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): ITGA5.

Top Reactome pathways

26 total, by targets touching each:

Pathway	Targets	Genes
Hemostasis	1	ITGA5
Developmental Biology	1	ITGA5
Extracellular matrix organization	1	ITGA5
Elastic fibre formation	1	ITGA5
Fibronectin matrix formation	1	ITGA5
Signal Transduction	1	ITGA5
Cell surface interactions at the vascular wall	1	ITGA5
Generic Transcription Pathway	1	ITGA5
Integrin cell surface interactions	1	ITGA5
Signaling by GPCR	1	ITGA5
L1CAM interactions	1	ITGA5
GPCR downstream signalling	1	ITGA5
G alpha (s) signalling events	1	ITGA5
Axon guidance	1	ITGA5
Signal transduction by L1	1	ITGA5
RNA Polymerase II Transcription	1	ITGA5
Gene expression (Transcription)	1	ITGA5
Transcriptional regulation by RUNX2	1	ITGA5
RUNX2 regulates genes involved in cell migration	1	ITGA5
Cellular responses to stimuli	1	ITGA5
GPER1 signaling	1	ITGA5
Nervous system development	1	ITGA5
Cellular responses to mechanical stimuli	1	ITGA5
Mechanical load activates signaling by PIEZO1 and integrins in osteocytes	1	ITGA5
Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells	1	ITGA5
Response of endothelial cells to shear stress	1	ITGA5

Dominant GO biological processes

GO term	Targets
angiogenesis	1
autophagy	1
cell-substrate junction assembly	1
cell adhesion	1
heterophilic cell-cell adhesion	1
leukocyte cell-cell adhesion	1
cell-matrix adhesion	1
integrin-mediated signaling pathway	1
female pregnancy	1
memory	1
negative regulation of autophagy	1
positive regulation of cell-substrate adhesion	1
response to muscle activity	1
CD40 signaling pathway	1
positive regulation of cell migration	1

Indications & clinical

Indications

7 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
melanoma	2	MONDO:0005105	EFO:0000756
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
peritoneal neoplasm	2	MONDO:0006901	EFO:1001100
ovarian cancer	2	MONDO:0008170	MONDO:0008170
lung neoplasm	2	MONDO:0021117	MONDO:0008903
age-related macular degeneration	1	MONDO:0005150	EFO:0001365
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE2	5
PHASE1/PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00100685	PHASE2	TERMINATED	Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)
NCT00278187	PHASE2	UNKNOWN	Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00369395	PHASE2	TERMINATED	A Study of Volociximab in Metastatic Melanoma
NCT00401570	PHASE2	COMPLETED	A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer
NCT00516841	PHASE2	TERMINATED	A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
NCT00635193	PHASE1/PHASE2	COMPLETED	Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)
NCT00782093	PHASE1	COMPLETED	A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration
NCT05077995	Not specified	COMPLETED	Validity and Reliability of the Polar M200 Activity Monitor

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

3 molecules share ≥1 primary target. Top 3 by shared-target count:

Molecule	Source	Status	Shared targets
BUPROPION	ChEMBL + PubChem	Phase 4 (approved)	ITGA5
CILENGITIDE	ChEMBL	Phase 3	ITGA5
Tirofiban	PubChem	Approved	ITGA5